基于内质网应激-FXR途径探讨山柰酚改善高脂饮食诱导的肝脏脂质沉积的机制

doi:10.3969/j.issn.1006-5725.2025.16.007

摘要/Abstract

摘要：

目的本实验基于内质网应激-FXR途径探讨山柰酚（kaempferol， KAE）对高脂饮食诱导的小鼠肝脏脂质沉积的保护作用及其机制。方法高脂饲料喂养C57BL/6J雄性小鼠22周建立慢性非酒精性脂肪性肝炎（non-alcoholic steatohepatitis， NASH）模型，同时以不同浓度的KAE灌胃8周进行干预。评估肝脏脂质沉积变化，检测肝脏内质网应激相关蛋白表达，法尼醇X受体（farnesoid x receptor， FXR）信号活化情况和脂质合成相关基因的表达。在体外，以棕榈酸（palmitic acid， PA）刺激AML-12细胞诱导肝细胞脂质沉积。用siRNA干扰AML-12细胞FXR的表达，以评估KAE对内质网应激-FXR信号途径的作用。结果 KAE显著抑制了高脂饮食引起的小鼠体质量快速增长，降低血清总胆固醇（TC）、总甘油三酯（TG）含量和谷丙转氨酶（ALT）活性（P < 0.05），有效改善肝脏大面积脂质沉积现象，对NASH小鼠肝脏脂质沉积具有保护作用。KAE降低肝脏GRP78、CHOP、p-PERK蛋白表达（P < 0.05），促进FXR及其活化标记蛋白质SHP的表达（P < 0.05），从而抑制脂肪酸合成酶（fatty acid synthase， FASN）的表达（P < 0.01），降低肝脏的脂合成。细胞实验显示，KAE能够降低PA暴露下AML-12细胞的内质网应激反应，提高FXR的表达和活性，抑制FASN的表达，进而抑制脂质合成。而FXR的敲除消除了KAE对SHP的促进作用和SHP介导的SREBP1c表达的抑制，进而消除了KAE对PA作用下AML-12细胞脂质沉积的保护作用。结论 KAE通过缓解高脂环境下肝细胞的内质网应激，促进FXR/SHP信号通路，从而抑制脂质合成，改善肝脏脂质沉积，提示KAE具有成为防治NASH肝脏脂质沉积药物的潜力。

关键词: 山柰酚, 内质网应激, FXR, 非酒精性脂肪性肝炎, 脂肪沉积

Abstract:

Objective To investigate the protective effects of Kaempferol （KAE） against hepatic lipid deposition induced by a high-fat diet， as well as the underlying mechanisms. Methods C57BL/6J male mice were fed a high-fat diet for 22 weeks to establish a chronic nonalcoholic steatohepatitis （NASH） model. KAE was administered during the last 8 weeks as an interventional agent to evaluate its effects. Liver lipid deposition was assessed， and the expression levels of endoplasmic reticulum （ER） stress-related proteins， activation of the Farnesoid X Receptor （FXR） signaling pathway， and the expression of lipid synthesis-related genes were analyzed. In vitro， palmitic acid （PA） was used to stimulate AML-12 cells to induce lipid accumulation. Additionally， siRNA targeting FXR was transfected into AML-12 cells to investigate the role of the ER stress-FXR signaling pathway in mediating the effects of KAE. Results The intervention of kaempferol inhibited the rapid weight gain induced by a high-fat diet， reduced serum total cholesterol， triglyceride levels， and ALT activity， effectively alleviated large-scale lipid aggregation in the liver， thereby exerting a protective effect against hepatic lipid deposition in NASH. Mechanistically， KAE decreased hepatic ER stress， promoted the expression of FXR and its activation marker SHP， thereby suppressing the expression of FASN and reducing hepatic lipid synthesis. In vitro， KAE treatment significantly reversed the inhibitory effect of excessive ER stress on FXR activity， as evidenced by the upregulation of FXR activity leading to decreased FASN expression and reduced steatosis in AML-12 cells. Moreover， FXR knockdown markedly abolished the protective effects of KAE on lipid deposition in AML-12 cells exposed to PA， by eliminating the promoting effect of KAE on SHP expression and the SHP-mediated suppression of SREBP1c. Conclusions KAE treatment alleviated ER stress， thereby enhancing FXR/SHP signaling and subsequently suppressing lipid synthesis to reduce hepatic lipid accumulation. These findings suggest that KAE holds therapeutic potential for the management of hepatic steatosis in NASH.

Key words: kaempferol, endoplasmic reticulum stress, farnesoid x receptor, non-alcoholic steatohepatitis, lipid deposition

中图分类号:

R363

周诗楠,梁露,钟文艳,陈晶晶,肖莉. 基于内质网应激-FXR途径探讨山柰酚改善高脂饮食诱导的肝脏脂质沉积的机制[J]. 实用医学杂志, 2025, 41(16): 2481-2488.

Shinan ZHOU,Lu LIANG,Wenyan ZHONG,Jingjing CHEN,Li. XIAO. Mechanism of kaempferol ameliorating hepatic lipid deposition induced by high fat diet based on endoplasmic reticulum stress-FXR pathway[J]. The Journal of Practical Medicine, 2025, 41(16): 2481-2488.

图/表 5

表1

图1

图2

图3

图4

参考文献 30

[1]	ENGIN A. Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis［J］. Adv Exp Med Biol， 2024， 1460：539-574. doi:10.1007/978-3-031-63657-8_18 doi: 10.1007/978-3-031-63657-8_18
[2]	TENG M L， NG C H， HUANG D Q， et al. Global incidence and prevalence of nonalcoholic fatty liver disease［J］. Clin Mol Hepatol， 2023， 29（）：S32-S42. doi:10.3350/cmh.2022.0365 doi: 10.3350/cmh.2022.0365
[3]	WEI S， WANG L， EVANS P C， et al. NAFLD and NASH： etiology， targets and emerging therapies［J］. Drug Discov Today， 2024， 29（3）：103910. doi:10.1016/j.drudis.2024.103910 doi: 10.1016/j.drudis.2024.103910
[4]	AJOOLABADY A， KAPLOWITZ N， LEBEAUPIN C， et al. Endoplasmic reticulum stress in liver diseases［J］. Hepatology， 2023， 77（2）：619-639. doi:10.1002/hep.32562 doi: 10.1002/hep.32562
[5]	李霞，李映，何伟，等.糖蛋白130在急性肝损伤中负性调控内质网应激作用及机制［J］.实用医学杂志，2022，38（12）：1499-1505.
[6]	PARTHASARATHY G， MALHI H. Assessment of Lipotoxic Endoplasmic Reticulum （ER） Stress in Nonalcoholic Steatohepatitis （NASH）［J］. Methods Mol Biol， 2022， 2455：243-254. doi:10.1007/978-1-0716-2128-8_19 doi: 10.1007/978-1-0716-2128-8_19
[7]	MERENDA T， JUSZCZAK F， FERIER E， et al. Natural compounds proposed for the management of non-alcoholic fatty liver disease［J］. Nat Prod Bioprospect， 2024， 14（1）：24. doi:10.1007/s13659-024-00445-z doi: 10.1007/s13659-024-00445-z
[8]	YAO Y X， YU Y J， DAI S， et al. Kaempferol efficacy in metabolic diseases： Molecular mechanisms of action in diabetes mellitus， obesity， non-alcoholic fatty liver disease， steatohepatitis， and atherosclerosis［J］. Biomed Pharmacother， 2024， 175：116694. doi:10.1016/j.biopha.2024.116694 doi: 10.1016/j.biopha.2024.116694
[9]	SHIN S K， KWON E Y. Kaempferol ameliorates metabolic syndrome by inhibiting inflammation and oxidative stress in high-fat diet-induced obese mice［J］. Nutr Res Pract， 2024， 18（3）：325-344. doi:10.4162/nrp.2024.18.3.325 doi: 10.4162/nrp.2024.18.3.325
[10]	XIANG H， SHAO M， LU Y， et al. Kaempferol Alleviates Steatosis and Inflammation During Early Non-Alcoholic Steatohepatitis Associated With Liver X Receptor α-Lysophosphatidylcholine Acyltransferase 3 Signaling Pathway［J］. Front Pharmacol， 2021， 12：690736. doi:10.3389/fphar.2021.690736 doi: 10.3389/fphar.2021.690736
[11]	TIE F， DING J， HU N， et al. Kaempferol and Kaempferide Attenuate Oleic Acid-Induced Lipid Accumulation and Oxidative Stress in HepG2 Cells［J］. Int J Mol Sci， 2021， 22（16）：8847. doi:10.3390/ijms22168847 doi: 10.3390/ijms22168847
[12]	WANG H， CHEN L， ZHANG X， et al. Kaempferol protects mice from d-GalN/LPS-induced acute liver failure by regulating the ER stress-Grp78-CHOP signaling pathway［J］. Biomed Pharmacother， 2019， 111：468-475. doi:10.1016/j.biopha.2018.12.105 doi: 10.1016/j.biopha.2018.12.105
[13]	CAO R， CAO C， HU X， et al. Kaempferol attenuates carbon tetrachloride （CCl（4））-induced hepatic fibrosis by promoting ASIC1a degradation and suppression of the ASIC1a-mediated ERS［J］. Phytomedicine， 2023， 121：155125. doi:10.1016/j.phymed.2023.155125 doi: 10.1016/j.phymed.2023.155125
[14]	XIE X， LIAO Y， LIN Z， et al. Patchouli alcohol alleviates metabolic dysfunction-associated steatohepatitis via inhibiting mitochondria-associated endoplasmic reticulum membrane disruption-induced hepatic steatosis and inflammation in rats［J］. Int Immunopharmacol， 2024， 138：112634. doi:10.1016/j.intimp.2024.112634 doi: 10.1016/j.intimp.2024.112634
[15]	XIONG X， WANG X， LU Y， et al. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice［J］. J Hepatol， 2014， 60（4）：847-854. doi:10.1016/j.jhep.2013.12.003 doi: 10.1016/j.jhep.2013.12.003
[16]	ISRAELSEN M， FRANCQUE S， TSOCHATZIS E A， et al. Steatotic liver disease［J］. Lancet， 2024， 404（10464）：1761-1778. doi:10.1016/s0140-6736(24)01811-7 doi: 10.1016/s0140-6736(24)01811-7
[17]	XIA S W， WANG Z M， SUN S M， et al. Endoplasmic reticulum stress and protein degradation in chronic liver disease［J］. Pharmacol Res， 2020， 161：105218. doi:10.1016/j.phrs.2020.105218 doi: 10.1016/j.phrs.2020.105218
[18]	CHEN H， TAN H， WAN J， et al. PPAR-γ signaling in nonalcoholic fatty liver disease： Pathogenesis and therapeutic targets［J］. Pharmacol Ther， 2023， 245：108391. doi:10.1016/j.pharmthera.2023.108391 doi: 10.1016/j.pharmthera.2023.108391
[19]	LI X， XU Z， WANG S， et al. Emodin ameliorates hepatic steatosis through endoplasmic reticulum-stress sterol regulatory element-binding protein 1c pathway in liquid fructose-feeding rats［J］. Hepatol Res， 2016， 46（3）：E105-E117. doi:10.1111/hepr.12538 doi: 10.1111/hepr.12538
[20]	VARGHESE D S， OOMMEN D， JOHN A， et al. GRP78/BiP alleviates oxLDL-induced hepatotoxicity in familial hypercholesterolemia caused by missense variants of LDLR in a HepG2 cellular model［J］. Lipids Health Dis， 2023， 22（1）：69. doi:10.1186/s12944-023-01835-x doi: 10.1186/s12944-023-01835-x
[21]	WANG D， LAO L， PANG X， et al. Asiatic acid from Potentilla chinensis alleviates non-alcoholic fatty liver by regulating endoplasmic reticulum stress and lipid metabolism［J］. Int Immunopharmacol， 2018， 65：256-267. doi:10.1016/j.intimp.2018.10.013 doi: 10.1016/j.intimp.2018.10.013
[22]	GIOIELLO A， ROSATELLI E， CERRA B. Patented Farnesoid X receptor modulators： A review （2019 - present）［J］. Expert Opin Ther Pat， 2024， 34（7）：547-564. doi:10.1080/13543776.2024.2314296 doi: 10.1080/13543776.2024.2314296
[23]	牛春燕，石永强，陈跃.非酒精性脂肪性肝病的新兴靶向治疗药物研究进展［J］.实用医学杂志，2022，38（11）：1439-1442.
[24]	CHEN S， SUN S， FENG Y， et al. Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C/PPARα/CD36 pathway［J］. Eur J Pharmacol， 2023， 952：175808. doi:10.1016/j.ejphar.2023.175808 doi: 10.1016/j.ejphar.2023.175808
[25]	HAGA S， YIMIN， OZAKI M. Relevance of FXR-p62/SQSTM1 pathway for survival and protection of mouse hepatocytes and liver， especially with steatosis［J］. BMC Gastroenterol， 2017， 17（1）：9. doi:10.1186/s12876-016-0568-3 doi: 10.1186/s12876-016-0568-3
[26]	KIM K H， CHOI S， ZHOU Y， et al. Hepatic FXR/SHP axis modulates systemic glucose and fatty acid homeostasis in aged mice［J］. Hepatology， 2017， 66（2）：498-509. doi:10.1002/hep.29199 doi: 10.1002/hep.29199
[27]	ADORINI L， TRAUNER M. FXR agonists in NASH treatment［J］. J Hepatol， 2023， 79（5）：1317-1331. doi:10.1016/j.jhep.2023.07.034 doi: 10.1016/j.jhep.2023.07.034
[28]	KREMOSER C. FXR agonists for NASH： How are they different and what difference do they make？［J］. J Hepatol， 2021， 75（1）：12-15. doi:10.1016/j.jhep.2021.03.020 doi: 10.1016/j.jhep.2021.03.020
[29]	MOHAMMADPOUR-ASL S， ROSHAN-MILANI B， ROSHAN-MILANI S， et al. Endoplasmic reticulum stress PERK-ATF4-CHOP pathway is involved in non-alcoholic fatty liver disease in type 1 diabetic rats： The rescue effect of treatment exercise and insulin-like growth factor I［J］. Heliyon， 2024， 10（5）：e27225. doi:10.1016/j.heliyon.2024.e27225 doi: 10.1016/j.heliyon.2024.e27225
[30]	HAN C Y， RHO H S， KIM A， et al. FXR Inhibits Endoplasmic Reticulum Stress-Induced NLRP3 Inflammasome in Hepatocytes and Ameliorates Liver Injury［J］. Cell Rep， 2018， 24（11）：2985-2999. doi:10.1016/j.celrep.2018.07.068 doi: 10.1016/j.celrep.2018.07.068

基因	序列 (5’ to 3’)
TNF?ɑ	正向	CCTGTAGCCCACGTCGTAG
	反向	GGGAGTAGACAAGGTACAACCC
IL?1β	正向	GAAATGCCACCTTTTGACAGTG
	反向	CTGGATGCTCTCATCAGGACA
GAPDH	正向	TCAAGAAGGGTGGTGAAGG
	反向	TCAAAGGGTGGAGGGGGGGGGTGGTT